Mark Corbett is an Independent Pharmaceutical Consultant with over 20 years’ industry experience, who has specialized for over eight years in the area of access to unlicensed medicines, Named Patient / Early Access / Expanded Access and Compassionate Use Programs.
Mark’s recent roles have been as part of the senior leadership team for the Clinigen Group plc. Having joined Clinigen in mid-2010, on the acquisition of Idis by Clinigen in April 2015 Mark moved to Managing Director of Idis Global Access part of Clinigen Group plc. In this role he had overall commercial, financial and operational responsibility for Idis Global Access Division, which specialised in compliant, ethical access to unlicensed medicines for healthcare professionals treating patient with unmet medical need. Prior to this Mark was Senior Vice President and established Clinigen’s Global Access Programs Division which specialised in the consultancy, development, set up and implementation of access programs on behalf of the biotech and pharmaceutical industries, alongside oversight of Clinigen’s Global Customer Services. Mark was also a member of Clinigen’s Operational Board responsible for the taking Clinigen through its AIM stock market flotation in September 2012. Prior to joining Clinigen, Mark was the Head of European Business Development and a Global Account Director at Idis.
Mark has gained extensive specialist knowledge and operational expertise in implementation of more than 150 Global Named Patient / Early Access / Expanded Access and Compassionate Use Programs for a variety of clients ranging from niche biotech to global pharmaceutical companies; alongside gaining a detailed understanding of the supply of unlicensed medicines on a global basis.
Mark is widely recognised as a thought leader on the subject of unlicensed medicines supply, Named Patient / Early Access / Expanded Access and Compassionate Use Programs having published extensively and spoken at a number of industry focused webinars, congresses and workshops.